Medical Oncology

Duke

Questions discussed in this category

When would you use PSMA PET over conventional imaging for prostate cancer?

Would you use it for initial staging or at time of biochemical recurrence?

2 Answers available

How do you define cisplatin ineligibility for muscle invasive bladder cancer?

1 Answer available

In light of ARASENS presented at GU ASCO 2022, how do you approach treatment of de novo metastatic hormone sensitive prostate cancer?

1 Answer available

How does the FDA approval of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) change how you image and manage patients with metastatic castrate-resistant prostate cancer?

When do you order PSMA PET? Will you preferably order Locametz (gallium Ga 68 gozetotide) PET?

1 Answer available

For urothelial carcinoma with squamous differentiation, what chemotherapy do you give for chemoradiation?

2 Answers available

How do you manage patients with oligometastatic renal cell carcinoma after nephrectomy and metastatectomy?

Do you observe, offer adjuvant pembrolizumab, or give a first-line metastatic regimen (IO/IO or IO/TKI)? Does your recommendation vary based on risk c...

1 Answer available

What is your approach to the treatment of metastatic renal cell carcinoma with unclassified histology?

1 Answer available

Would you recommend surgery or radiation for newly diagnosed localized prostate cancer diagnosed on a urethral lesion biopsy?

GS 4+4. PSA low (1-2). CT and bone scan negative for lymphadenopathy or metastatic disease. Prostate MRI pending.

2 Answers available

What is your preferred treatment for Stage IIA seminoma or IIB seminoma with LN <3 cm and normal tumor markers after orchiectomy?

Does patient age effect your approach? Would you consider RPLND for any patients in light of the phase II SEMS trial presented at the 2021 ASCO GU Ca...

3 Answers available

How would you sequence therapies for a patient with chemotherapy-naive metastatic castration-resistant prostate cancer who is MSI-H on tissue-based NGS?

What line would you give pembrolizumab?

1 Answer available

For a patient who is cisplatin-eligible with localized, high-grade upper tract urothelial carcinoma, but no muscularis propria seen on biopsy, what is your approach?

What neoadjuvant or adjuvant therapy would you give?

1 Answer available

What second line therapy would you use for metastatic clear cell RCC after a 6-12 month response to ipilimumab/nivolumab followed by development of multiple bone metastases but stable soft tissue disease?

Ex: TKI alone, TKI + checkpoint inhibitor, checkpoint inhibitor alone, TKI + mTOR inhibitor. Please specify drug regimen, if applicable.

2 Answers available

How do you manage a young patient with mediastinal nonseminomatous germ cell tumor that has relapsed after primary treatment with four cycles of VIP?

1 Answer available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001-03-15

Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis.

Clin Nutr, 2015 Aug 28

The association of substituting carbohydrates with total fat and different types of fatty acids with mortality and weight change among diabetes patients.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-03-10

Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.

Clinical genitourinary cancer, 2018-12

Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery.

J Urol, 2020 Apr

Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma.

Lancet, 2020 Mar 05

Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial.

Oncologist, 2020 Dec 03

Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer.

Urology, 2000-11-01

Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies.

Abdom Radiol (NY), 2019 Aug 29

Apical periurethral transition zone lesions: MRI and histology findings.

J Urol, 2021 Feb 26

A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with F-DCFPyL in Prostate Cancer Patients (OSPREY).

Eur Urol Oncol, 2019 Sep 19

Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study.

N Engl J Med,

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

N. Engl. J. Med., 2012-04-19

Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.

European urology, 2017-07

Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy.

Lancet, 2016 Mar 19

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

The New England journal of medicine, 2017-07-27

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-04-10

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

N. Engl. J. Med., 2019 Jun 02

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

N. Engl. J. Med., 2019 May 31

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

J. Clin. Oncol., 2019 Jul 22

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.

N Engl J Med, 2022 Feb 17

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-06-10

Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

Clinical genitourinary cancer, 2018-08

Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function.

Related Topics in Medical Oncology